About: Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens
Creator	Booy, Robert Dalton, Richard Dixit, Rashmi Herz, Jenny
source	Elsevier; Medline; PMC
abstract	Abstract Background Passive immunotherapy using polyclonal antibodies (immunoglobulins) has been used for over a century in the treatment and post-exposure prophylaxis of various infections and toxins. Heterologous polyclonal antibodies are obtained from animals hyperimmunised with a pathogen or toxin. Aims The aims of this review are to examine the history of animal polyclonal antibody therapy use, their development into safe and effective products and the potential application to humans for emerging and neglected infectious diseases. Methods A literature search of OVID Medline and OVID Embase databases was undertaken to identify articles on the safety, efficacy and ongoing development of polyclonal antibodies. The search contained database-specific MeSH and EMTREE terms in combination with pertinent text-words: polyclonal antibodies and rare/neglected diseases, antivenins, immunoglobulins, serum sickness, anaphylaxis, drug safety, post marketing surveillance, rabies, human influenza, Dengue, West Nile, Nipah, Hendra, Marburg, MERS, Hemorrhagic Fever Virus, and Crimean-Congo. No language limits were applied. The final search was completed on 20.06.2015. Of 1960 articles, title searches excluded many irrelevant articles, yielding 303 articles read in full. Of these, 179 are referenced in this study. Results Serum therapy was first used in the 1890s against diphtheria. Early preparation techniques yielded products contaminated with reactogenic animal proteins. The introduction of enzymatic digestion, and purification techniques substantially improved their safety profile. The removal of the Fc fragment of antibodies further reduces hypersensitivity reactions. Clinical studies have demonstrated the efficacy of polyclonal antibodies against various infections, toxins and venoms. Products are being developed against infections for which prophylactic and therapeutic options are currently limited, such as avian influenza, Ebola and other zoonotic viruses. Conclusions Polyclonal antibodies have been successfully applied to rabies, envenomation and intoxication. Polyclonal production provides an exciting opportunity to revolutionise the prognosis of both longstanding neglected tropical diseases as well as emerging infectious threats to humans.
has issue date	2016-02-24(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2016.01.016
bibo:pmid	26802604
has license	els-covid
sha1sum (hex)	c79b541523d38fd66a8ccb50ab64c6643b76af7d
schema:url	https://doi.org/10.1016/j.vaccine.2016.01.016
resource representing a document's title	Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens
has PubMed Central identifier	PMC7131169
has PubMed identifier	26802604
schema:publication	Vaccine
resource representing a document's body	covid:c79b541523d38fd66a8ccb50ab64c6643b76af7d#body_text
is schema:about of	named entity 'HETEROLOGOUS' named entity 'DEVELOPMENT' named entity 'TO EXAMINE' named entity 'HISTORY OF' named entity 'METHODS' »more»

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software